Fertility and Sterility
Volume 91, Issue 4 , Pages 1012-1017 , April 2009

Endometrin for luteal phase support in a randomized, controlled, open-label, prospective in-vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation

  • Kevin J. Doody, M.D.

      Affiliations

    • Center for Assisted Reproduction, Bedford, Texas
    • ,
  • Vicki L. Schnell, M.D.

      Affiliations

    • Center of Reproductive Medicine, Webster, Texas
    • ,
  • Russell A. Foulk, M.D.

      Affiliations

    • Nevada Center for Reproductive Medicine, Reno, Nevada
    • ,
  • Charles E. Miller, M.D.

      Affiliations

    • Charles Miller & Associates, Arlington Heights, Illinois
    • ,
  • Bradford A. Kolb, M.D.

      Affiliations

    • Huntington Reproductive Center, Pasadena, California
    • ,
  • Emily J. Blake, M.D.

      Affiliations

    • Ferring Pharmaceuticals, Inc., Parsippany, New Jersey
    • Corresponding Author InformationReprint requests: Emily J. Blake, M.D., Ferring Pharmaceuticals, Inc., 4 Gatehall Drive, 3rd Floor, Parsippany, NJ 07054 (FAX: 973-796-1663).
    • ,
  • Vladimir I. Yankov, M.D.

      Affiliations

    • Ferring Pharmaceuticals, Inc., Parsippany, New Jersey

Received 25 November 2007 ,Revised 17 January 2008 ,Accepted 17 January 2008.

References 

  1. Soliman S, Daya S, Collins J, Hughes EG. The role of luteal phase support in infertility treatment: a meta-analysis of randomized trials. Fertil Steril. 1994;61:1068–1076
  2. Penzias AS. Luteal phase support. Fertil Steril. 2002;77:318–323
  3. Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod. 2002;17:2287–2299
  4. Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod. 1997;12:1073–1079
  5. Mahaguna V, McDermott JM, Zhang F, Ochoa F. Investigation of product quality between extemporaneously compounded progesterone vaginal suppositories and an approved progesterone vaginal gel. Drug Dev Ind Pharm. 2004;30:1069–1078
  6. Preston RA, Norris PM, Blake EJ, Yankov VI. Single day and multiple day pharmacokinetics of a novel vaginal micronized progesterone tablet (Endometrin) compared to Crinone vaginal gel in healthy female subjects. Reprod Sci. 2007;14(Suppl):198A
  7. Levy T, Gurevitch S, Bar-Hava I, Ashkenazi J, Magazanik A, Homburg R, et al. Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. Hum Reprod. 1999;14:606–610
  8. Meldrum DR. Female reproductive aging—ovarian and uterine factors. Fertil Steril. 1993;59:1–5
  9. Centers for Disease Control and Prevention. 2005 assisted reproductive technology (ART) report: national summary. Available at: http://apps.nccd.cdc.gov/ART2005/nation05.asp. Last accessed: February 14, 2008.

 E.J.B. and V.I.Y are employees of Ferring Pharmaceuticals. C.E.M. receives grant support from Ferring Pharmaceuticals, acts as a consultant for Ferring Pharmaceuticals, Ethicon Endo Surgery, Ethicon Women's Health and Urology, Smith & Nephew, Galil Medical, and Boston Scientific, and serves on speakers bureaus for Boston Scientific, Ferring Pharmaceuticals, Ethicon Endo Surgery, and Ethicon Women's Health and Urology. K.J.D. has nothing to disclose. V.L.S. has nothing to disclose. R.A.F. has nothing to disclose. B.A.K. has nothing to disclose.

 Endometrin, Menopur, Bravelle: Ferring Pharmaceuticals, Parsippany, NJ.

PII: S0015-0282(08)00163-5

doi: 10.1016/j.fertnstert.2008.01.069

Fertility and Sterility
Volume 91, Issue 4 , Pages 1012-1017 , April 2009

Article Tools